At Frontage, our scientific team has over a decade of experience in Microbiome to help you solve the development problems of therapeutics, probiotics and prebiotics.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
The microbiome continuously shapes its environment through a complex set of interactions, and the microbial flora within and outside the human body has an essential relationship to an organism’s health status. For instance, dysbiosis in the gut microflora is an established contributor to the development of pathological conditions such as chronic inflammatory bowel diseases, type 2 diabetes, and colorectal cancer. In the drug discovery industry, scientists must be proactive in detecting changes in the intestinal microbiome in response to novel therapeutics. Changes to the microbiome associated with probiotic and prebiotic administration must be carefully monitored. Characterizing changes to the gut microbiome whether by metabolic, enzymatic, biomarker, or genomic approaches is fraught with difficulty and has a high assay development and validation cost. Therefore, many companies have looked to partner with research organizations that have success with innovative microbiome analysis tools.
In this webinar, our distinguished speakers, Dr. David Kwok and Dr. David Willoughby discuss current biomarker identification and metabolic evaluation techniques of the human gut microbiome, as well as metagenomic sequencing modalities utilized to streamline results for expedited interpretation and analysis.
The human gut microbiome contains a complex aggregate of colonic bacterial enzymes mediating the metabolism of a wide range of xenobiotics and dietary components. This webinar highlights examples of pre-systematic drug clearance mediated by colonic enzymes contributing to systemic metabolite exposure, examines evidence of a causative link between dysbiosis and metabolic disorders, and concludes with an overview of established gut microbiome biomarkers and assay panels available to support investigations in understanding the metabolic fate of xenobiotics and colonic bacterial secondary metabolites.
Regulated preclinical developmental and reproductive toxicity (DART) studies using mammalian research models are an important step to take before initiating clinical trials. Frontage’s scientists have over 20 years of experience running DART studies with knowledge of accurately estimating test doses, showing formulation stability, and expertise in animal handling. Our labs have the extensive capacity to run many studies, helping our sponsors meet their timelines with uncompromising quality.